Tissue selective drug delivery utilizing carrier-mediated transport systems

Journal of Controlled Release

Volumn 62, Issue 1-2, 1999, Pages 239-244

  Tsuji, Akira ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Lactam antibiotics; HMG CoA reductase inhibitors; New quinolones; Oligopeptide transporter; P Glycoprotein; Tumor cells

Indexed keywords

5 AMINO 7 (7 AMINO 5 AZASPIRO[2.4]HEPT 5 YL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHYL 4 OXO 3 QUINOLINECARBOXYLIC ACID; BETA LACTAM ANTIBIOTIC; CARNOSINE; DRUG CARRIER; GLYCYLSARCOSINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVODOPA PHENYLALANINE; OLIGOPEPTIDE; PHENYLALANINE DERIVATIVE; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CANCER CELL CULTURE; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; DRUG TRANSPORT; INTESTINE ABSORPTION; LUNG ALVEOLUS CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE SPECIFICITY; XENOPUS LAEVIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; BRAIN; CARRIER PROTEINS; DIPEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINES; LACTAMS; LIVER; ORGAN SPECIFICITY; PRAVASTATIN; RATS; SYMPORTERS; TUMOR CELLS, CULTURED; XENOPUS LAEVIS;

EID: 0032861503     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00043-7     Document Type: Article

References (24)

1. Tsuji A., Tamai I. Carrier-mediated intestinal transport of drugs. Pharm. Res. 13:1996;963-977.
2. Tamai I., Tsuji A. Carrier-mediated approaches for oral drug delivery. Adv. Drug Deliv. Rev. 20:1996;5-32.
3. Tamai I., Tsuji A. Drug delivery through the blood-brain barrier. Adv. Drug Deliv. Rev. 19:1996;401-424.
4. Miyamoto K., Shiraga T., Yamamoto H., Haga H., Taketani Y., Morita K., Tamai I., Sai Y., Tsuji A., Takeda E. Sequence, tissue distribution and developmental changes in rat intestinal oligopeptide transporter. Biochem. Biophys. Acta. 1305:1996;34-38.
5. +/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J. Biol. Chem. 270:1995;6456-6463.
6. Sai Y., Tamai I., Sumikawa H., Hayashi K., Nakanishi T., Amano O., Numata M., Iseki S., Tsuji A. Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption of β-lactam antibiotics. FEBS Lett. 392:1996;25-29.
7. Tamai I., Hayashi K., Terao T., Sai Y., Shiraga T., Miyamoto K., Takeda E., Higashida H., Tsuji A. Predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of β-lactam antibiotics in rat small intestine. J. Pharm. Pharmacol. 49:1997;796-801.
8. Kohno Y., Yoshida H., Suwa T., Suga T. Uptake of clarithromycin by lung cells. J. Antimicrob. Chemother. 26:1990;503-513.
9. Yamaoka K., Tanigawara Y., Nakagawa Y., Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4:1981;879-885.
10. Fei Y-J., Kanai Y., Nussberger S., Ganapathy V., Leibach F.H., Romero M.F., Singh S.K., Boron W.F., Hediger M.A. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature. 368:1994;563-566.
11. +/peptide cotransporter mediating absorption of β-lactam antibiotics in the intestine and kidney. J. Pharmacol. Exp. Ther. 275:1995;1631-1637.
12. Wade D.N., Mearrick P.T., Morris J.L. Active transport of L-DOPA in the intestine. Nature. 242:1973;463-465.
13. Tsuji A., Tamai I., Nakanishi M., Amidon G.L. Mechanism of absorption of the dipeptide α-methyldopa-phe in intestinal brush-border membrane vesicles. Pharm. Res. 7:1990;308-309.
14. Wang H.P., Lu H.H., Lee J.S., Cheng C.Y., Mah J.R., Ku C.Y., Hsu W., Yen C.F., Lin C.J., Kuo H.S. Intestinal absorption studies on peptide mimetic α-methyldopa prodrug. J. Pharm. Pharmacol. 48:1996;270-276.
15. Takai I., Nakanishi T., Nakahara H., Sai Y., Ganapathy V., Leibach F.H., Tsuji A. Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1. J. Pharm. Sci. 87:1998;1542-1546.
16. Nakanaishi T., Tamai I., Sai Y., Sasaki T., Tsuji A. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Can. Res. 57:1997;4118-4122.
17. Saheki A., Terasaki T., Tamai I., Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 11:1994;305-311.
18. Koga T., Shimada Y., Kuroda M., Tsujita Y., Hasegawa Y., Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim. Biophys. Acta. 1045:1990;115-120.
19. Tamai I., Takanaga H., Maeda H., Ogihara T., Yoneda M., Tsuji A. Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm. Res. 12:1995;1727-1732.
20. Terasaki T., Kang Y.S., Ohnishi T., Tsuji T.A. In vitro evidence for carrier-mediated uptake of acidic drugs by isolated bovine brain capillaries. J. Pharm. Pharmacol. 43:1991;172-176.
21. Terasaki T., Takakura S., Moritani S., Tsuji A. Transport of mono-carboxylic acids at the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary endothelial cells. J. Pharm. Exp. Ther. 258:1991;932-937.
22. Tsuji A., Saheki A., Tamai I., Terasaki T. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors at the blood-brain barrier. J. Pharmcol. Exp. Ther. 267:1993;1085-1090.
23. Komai T., Shigehara E., Tokui T., Koga T., Ishigami M., Kuroiwa C., Horiuchi S. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem. Pharmacol. 43:1992;667-670.
24. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am. J. Physiol. 264:1993;G36-44.